Essa Pharma’s sole clinical-stage candidate was on track to fall short against Xtandi in a phase 2 prostate cancer trial, leading the biotech to terminate the study, abandon the candidate and ...

I had friends from various communities and met them on a daily basis,” Ruto’s co-lead Counsel Essa Faal quoted the witness’s initial statement. But the witness maintained that when he first ...

(RTTNews) - ESSA Pharma Inc. (EPIX) announced that it has made the decision to terminate the Phase 2 clinical trial evaluating in a 2:1 randomization masofaniten combined with enzalutamide versus ...

Antoinette Essa joined the CBS 6 family in September of 2009, as a reporter for the “A-List”, a segment featuring events in and around Central Virginia. In addition, she does daily blogs for ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

ESSA Pharma (NASDAQ:EPIX) plummeted about 70% premarket on Friday after ending its Phase 2 trial for a prostate cancer treatment. The trial tested masofaniten with enzalutamide versus enzalutamide ...

Mo Faal opened his goal account for Wrexham in style on Tuesday night, hitting a spectacular volley to round off a 3-0 EFL Trophy win against Wolverhampton Wanderers Under-21s. The 21-year-old ...

Investing.com -- ESSA Pharma (NASDAQ:EPIX), a biotechnology company focused on developing treatments for metastatic castration-resistant prostate cancer, saw its stock downgraded by major ...